Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis
Introduction: Increased biochemical bone turnover markers (BTMs) measured in serum are associated with bone loss, increased fracture risk and poor treatment adherence, but their role in clinical practice is presently unclear. The aim of this consensus group report is to provide guidance to clinician...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:223295 |
| Acceso en línea: | https://ddd.uab.cat/record/223295 https://dx.doi.org/urn:doi:10.1007/s12325-019-01063-9 |
| Access Level: | acceso abierto |
| Palabra clave: | Algorithm Bone Bone biomarker CTX Osteoporosis P1NP Rheumatology |
| id |
ES_0a2e3489d8ac94a71c1eb3e2e1dce32e |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:223295 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for OsteoporosisLorentzon, Mattias|||0000-0003-0749-1431Branco, Jaime|||0000-0001-7024-4375Brandi, Maria Luisa|||0000-0002-8741-0592Bruyère, Olivier|||0000-0003-4269-9393Chapurlat, Roland|||0000-0001-8214-6385Cooper, Cyrus|||0000-0003-3510-0709Cortet, Bernard|||0000-0001-8912-0452Díez Pérez, Adolfo|||0000-0001-8162-0209Ferrari, Serge|||0000-0002-1372-4417Gasparik, A.Herrmann, M.Jorgensen, N. R.Kanis, J.Kaufman, Jean-MarcLaslop, A.Locquet, MedeaMatijevic, Radmila|||0000-0002-4993-9399McCloskey, E.Minisola, S.Pikner, R.Reginster, Jean-Yves|||0000-0001-6290-752XRizzoli, R.Szulc, PawelVlaskovska, M.Cavalier, Etienne|||0000-0003-0947-2226AlgorithmBoneBone biomarkerCTXOsteoporosisP1NPRheumatologyIntroduction: Increased biochemical bone turnover markers (BTMs) measured in serum are associated with bone loss, increased fracture risk and poor treatment adherence, but their role in clinical practice is presently unclear. The aim of this consensus group report is to provide guidance to clinicians on how to use BTMs in patient evaluation in postmenopausal osteoporosis, in fracture risk prediction and in the monitoring of treatment efficacy and adherence to osteoporosis medication. Methods: A working group with clinical scientists and osteoporosis specialists was invited by the Scientific Advisory Board of European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Results: Serum bone formation marker PINP and resorption marker βCTX-I are the preferred markers for evaluating bone turnover in the clinical setting due to their specificity to bone, performance in clinical studies, wide use and relatively low analytical variability. BTMs cannot be used to diagnose osteoporosis because of low sensitivity and specificity, but can be of value in patient evaluation where high values may indicate the need to investigate some causes of secondary osteoporosis. Assessing serum levels of βCTX-I and PINP can improve fracture prediction slightly, with a gradient of risk of about 1.2 per SD increase in the bone marker in addition to clinical risk factors and bone mineral density. For an individual patient, BTMs are not useful in projecting bone loss or treatment efficacy, but it is recommended that serum PINP and βCTX-I be used to monitor adherence to oral bisphosphonate treatment. Suppression of the BTMs greater than the least significant change or to levels in the lower half of the reference interval in young and healthy premenopausal women is closely related to treatment adherence. Conclusion: In conclusion, the currently available evidence indicates that the principal clinical utility of BTMs is for monitoring oral bisphosphonate therapy.Universitat Autònoma de Barcelona 22019-01-0120192019-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/223295https://dx.doi.org/urn:doi:10.1007/s12325-019-01063-9reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2232952026-06-06T12:50:31Z |
| dc.title.none.fl_str_mv |
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis |
| title |
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis |
| spellingShingle |
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis Lorentzon, Mattias|||0000-0003-0749-1431 Algorithm Bone Bone biomarker CTX Osteoporosis P1NP Rheumatology |
| title_short |
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis |
| title_full |
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis |
| title_fullStr |
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis |
| title_full_unstemmed |
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis |
| title_sort |
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis |
| dc.creator.none.fl_str_mv |
Lorentzon, Mattias|||0000-0003-0749-1431 Branco, Jaime|||0000-0001-7024-4375 Brandi, Maria Luisa|||0000-0002-8741-0592 Bruyère, Olivier|||0000-0003-4269-9393 Chapurlat, Roland|||0000-0001-8214-6385 Cooper, Cyrus|||0000-0003-3510-0709 Cortet, Bernard|||0000-0001-8912-0452 Díez Pérez, Adolfo|||0000-0001-8162-0209 Ferrari, Serge|||0000-0002-1372-4417 Gasparik, A. Herrmann, M. Jorgensen, N. R. Kanis, J. Kaufman, Jean-Marc Laslop, A. Locquet, Medea Matijevic, Radmila|||0000-0002-4993-9399 McCloskey, E. Minisola, S. Pikner, R. Reginster, Jean-Yves|||0000-0001-6290-752X Rizzoli, R. Szulc, Pawel Vlaskovska, M. Cavalier, Etienne|||0000-0003-0947-2226 |
| author |
Lorentzon, Mattias|||0000-0003-0749-1431 |
| author_facet |
Lorentzon, Mattias|||0000-0003-0749-1431 Branco, Jaime|||0000-0001-7024-4375 Brandi, Maria Luisa|||0000-0002-8741-0592 Bruyère, Olivier|||0000-0003-4269-9393 Chapurlat, Roland|||0000-0001-8214-6385 Cooper, Cyrus|||0000-0003-3510-0709 Cortet, Bernard|||0000-0001-8912-0452 Díez Pérez, Adolfo|||0000-0001-8162-0209 Ferrari, Serge|||0000-0002-1372-4417 Gasparik, A. Herrmann, M. Jorgensen, N. R. Kanis, J. Kaufman, Jean-Marc Laslop, A. Locquet, Medea Matijevic, Radmila|||0000-0002-4993-9399 McCloskey, E. Minisola, S. Pikner, R. Reginster, Jean-Yves|||0000-0001-6290-752X Rizzoli, R. Szulc, Pawel Vlaskovska, M. Cavalier, Etienne|||0000-0003-0947-2226 |
| author_role |
author |
| author2 |
Branco, Jaime|||0000-0001-7024-4375 Brandi, Maria Luisa|||0000-0002-8741-0592 Bruyère, Olivier|||0000-0003-4269-9393 Chapurlat, Roland|||0000-0001-8214-6385 Cooper, Cyrus|||0000-0003-3510-0709 Cortet, Bernard|||0000-0001-8912-0452 Díez Pérez, Adolfo|||0000-0001-8162-0209 Ferrari, Serge|||0000-0002-1372-4417 Gasparik, A. Herrmann, M. Jorgensen, N. R. Kanis, J. Kaufman, Jean-Marc Laslop, A. Locquet, Medea Matijevic, Radmila|||0000-0002-4993-9399 McCloskey, E. Minisola, S. Pikner, R. Reginster, Jean-Yves|||0000-0001-6290-752X Rizzoli, R. Szulc, Pawel Vlaskovska, M. Cavalier, Etienne|||0000-0003-0947-2226 |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Universitat Autònoma de Barcelona |
| dc.subject.none.fl_str_mv |
Algorithm Bone Bone biomarker CTX Osteoporosis P1NP Rheumatology |
| topic |
Algorithm Bone Bone biomarker CTX Osteoporosis P1NP Rheumatology |
| description |
Introduction: Increased biochemical bone turnover markers (BTMs) measured in serum are associated with bone loss, increased fracture risk and poor treatment adherence, but their role in clinical practice is presently unclear. The aim of this consensus group report is to provide guidance to clinicians on how to use BTMs in patient evaluation in postmenopausal osteoporosis, in fracture risk prediction and in the monitoring of treatment efficacy and adherence to osteoporosis medication. Methods: A working group with clinical scientists and osteoporosis specialists was invited by the Scientific Advisory Board of European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Results: Serum bone formation marker PINP and resorption marker βCTX-I are the preferred markers for evaluating bone turnover in the clinical setting due to their specificity to bone, performance in clinical studies, wide use and relatively low analytical variability. BTMs cannot be used to diagnose osteoporosis because of low sensitivity and specificity, but can be of value in patient evaluation where high values may indicate the need to investigate some causes of secondary osteoporosis. Assessing serum levels of βCTX-I and PINP can improve fracture prediction slightly, with a gradient of risk of about 1.2 per SD increase in the bone marker in addition to clinical risk factors and bone mineral density. For an individual patient, BTMs are not useful in projecting bone loss or treatment efficacy, but it is recommended that serum PINP and βCTX-I be used to monitor adherence to oral bisphosphonate treatment. Suppression of the BTMs greater than the least significant change or to levels in the lower half of the reference interval in young and healthy premenopausal women is closely related to treatment adherence. Conclusion: In conclusion, the currently available evidence indicates that the principal clinical utility of BTMs is for monitoring oral bisphosphonate therapy. |
| publishDate |
2019 |
| dc.date.none.fl_str_mv |
2 2019-01-01 2019 2019-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/223295 https://dx.doi.org/urn:doi:10.1007/s12325-019-01063-9 |
| url |
https://ddd.uab.cat/record/223295 https://dx.doi.org/urn:doi:10.1007/s12325-019-01063-9 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869403149191610368 |
| score |
15,300719 |